Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer.

Gomez Marti JL; Michaels E; Nasrazadani A; Wander SA; Brufsky AM

doi:10.1016/j.ccell.2026.01.004

← 뒤로

Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer.

Cancer cell 2026 Vol.44(2) p. 254-256

Gomez Marti JL, Michaels E, Nasrazadani A, Wander SA, Brufsky AM

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are an integral first-line treatment for hormone receptor-positive metastatic breast cancer, though resistance eventually develops.

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Gomez Marti JL, Michaels E, et al. (2026). Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer.. Cancer cell, 44(2), 254-256. https://doi.org/10.1016/j.ccell.2026.01.004

MLA Gomez Marti JL, et al.. "Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer.." Cancer cell, vol. 44, no. 2, 2026, pp. 254-256.

PMID 41666874

DOI 10.1016/j.ccell.2026.01.004

Abstract

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are an integral first-line treatment for hormone receptor-positive metastatic breast cancer, though resistance eventually develops. In this issue of Cancer Cell, Fan et al. report results from LINUX, a randomized phase 2 trial applying an artificial intelligence digital pathology classification system to guide therapy after CDK4/6i progression.

MeSH Terms

Humans; Breast Neoplasms; Female; Artificial Intelligence; Erb-b2 Receptor Tyrosine Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Protein Kinase Inhibitors; Receptors, Progesterone; Receptors, Estrogen; Neoplasm Metastasis; Treatment Outcome